Terms: = Ovarian cancer AND BIRC3, AIP1, 330, ENSG00000023445, HIAP1, Q13489, MIHC, CIAP2, API2, cIAP2, MALT2, hiap-1, RNF49, HAIP1 AND Clinical Outcome
4 results:
1. clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse.
Hollis RL; Carmichael J; Meynert AM; Churchman M; Hallas-Potts A; Rye T; MacKean M; Nussey F; Semple CA; Herrington CS; Gourley C
Am J Obstet Gynecol; 2019 Sep; 221(3):245.e1-245.e15. PubMed ID: 31055034
[TBL] [Abstract] [Full Text] [Related]
2. Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2.
Cohen S; Bruchim I; Graiver D; Evron Z; Oron-Karni V; Pasmanik-Chor M; Eitan R; Bernheim J; Levavi H; Fishman A; Flescher E
J Mol Med (Berl); 2013 Mar; 91(3):357-68. PubMed ID: 23052480
[TBL] [Abstract] [Full Text] [Related]
3. Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites.
Ott MG; Marmé F; Moldenhauer G; Lindhofer H; Hennig M; Spannagl R; Essing MM; Linke R; Seimetz D
Int J Cancer; 2012 May; 130(9):2195-203. PubMed ID: 21702044
[TBL] [Abstract] [Full Text] [Related]
4. Increased cyclin D1 expression is associated with features of malignancy and disease recurrence in ovarian tumors.
Barbieri F; Cagnoli M; Ragni N; Foglia G; Bruzzo C; PedullĂ F; Alama A
Clin Cancer Res; 1999 Jul; 5(7):1837-42. PubMed ID: 10430089
[TBL] [Abstract] [Full Text] [Related]